Clinical Trial

Neoadjuvant PSMA-RLT in Oligometastatic PCa

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Prospective single-center phase II study to evaluate the PSA, imaging and pathological response, as well as oncological outcomes of systemic radioligand therapy \[177Lu\]Lu-PSMAI\&T (PSMA-RLT) in patients planned for radical prostatectomy (RP) for oligometastatic prostate cancer (PCa) diagnosed using \[68Ga\]Ga-PSMA-11 PET examination. Ten patients with oligometastatic primary PCa diagnosed using \[68Ga\]Ga-PSMA-11 PET-CT/MRI imaging will be included in this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-06.
Trial Details
NCT Number NCT06259123
Lead Sponsor Medical University of Vienna
Conditions Prostate Cancer
Enrollment 10 participants
Start Date 2024-02-01
Primary Completion 2027-01 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2024-02-15